Apolipoprotein E in diet-induced obesity: a paradigm shift from conventional perception

Abstract

Apolipoprotein E (APOE) is a major protein component of peripheral and brain lipoprotein transport systems. APOE in peripheral circulation does not cross the blood brain barrier or blood cerebrospinal fluid barrier. As a result, peripheral APOE expression does not affect brain APOE levels and vice versa. Numerous epidemiological studies suggest a key role of peripherally expressed APOE in the development and progression of coronary heart disease while brain APOE has been associated with dementia and Alzheimer’s disease. More recent studies, mainly in experimental mice, suggested a link between Apoe and morbid obesity. According to the latest findings, expression of human apolipoprotein E3 (APOE3) isoform in the brain of mice is associated with a potent inhibition of visceral white adipose tissue (WAT) mitochondrial oxidative phosphorylation leading to significantly reduced substrate oxidation, increased fat accumulation and obesity. In contrast, hepatically expressed APOE3 is associated with a notable shift of substrate oxidation towards non-shivering thermogenesis in visceral WAT mitochondria, leading to resistance to obesity. These novel findings constitute a major paradigm shift from the widely accepted perception that APOE promotes obesity via receptor-mediated postprandial lipid delivery to WAT. Here, we provide a critical review of the latest facts on the role of APOE in morbid obesity.

Keywords

apolipoprotein E / morbid obesity / white adipose tissue / energy metabolism

References

[1] Saely CH, Geiger K, Drexel H. Brown versus white adipose tissue: a mini-review[J]. Gerontology, 2012, 58(1): 15–23

[2] Heeren J, Münzberg H. Novel aspects of brown adipose tissue biology[J]. Endocrinol Metab Clin North Am, 2013, 42(1): 89–107

[3] Schulz TJ, Tseng YH. Brown adipose tissue: development, metabolism and beyond[J]. Biochem J, 2013, 453(2): 167–178

[4] Flachs P, Rossmeisl M, Kuda O, Stimulation of mitochondrial oxidative capacity in white fat independent of UCP1: a key to lean phenotype[J]. Biochim Biophys Acta, 2013, 1831(5): 986–1003

[5] Timmons JA, Wennmalm K, Larsson O, Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages[J]. Proc Natl Acad Sci U S A, 2007, 104(11): 4401–4406

[6] Seale P, Bjork B, Yang W, PRDM16 controls a brown fat/skeletal muscle switch[J]. Nature, 2008, 454(7207): 961–967

[7] Barbatelli G, Murano I, Madsen L, The emergence of cold-induced brown adipocytes in mouse white fat depots is determined predominantly by white to brown adipocyte transdifferentiation[J]. Am J Physiol Endocrinol Metab, 2010, 298(6): E1244–E1253

[8] Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification[J]. Biochemistry, 1981, 20(4): 1033–1041

[9] Raffai RL, Dong LM, Farese RV Jr, Introduction of human apolipoprotein E4 “domain interaction” into mouse apolipoprotein E[J]. Proc Natl Acad Sci U S A, 2001, 98(20): 11587–11591

[10] Dong LM, Wilson C, Wardell MR, Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms[J]. J Biol Chem, 1994, 269(35): 22358–22365

[11] Srivastava RA, Bhasin N, Srivastava N. Apolipoprotein E gene expression in various tissues of mouse and regulation by estrogen[J]. Biochem Mol Biol Int, 1996, 38(1): 91–101

[12] Smith JD, Melián A, Leff T, Expression of the human apolipoprotein E gene is regulated by multiple positive and negative elements[J]. J Biol Chem, 1988, 263(17): 8300–8308

[13] Xu Q, Bernardo A, Walker D, Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus[J]. J Neurosci, 2006, 26(19): 4985–4994

[14] Sun Y, Wu S, Bu G, Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins[J]. J Neurosci, 1998, 18(9): 3261–3272

[15] Maloney B, Ge YW, Alley GM, Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer’s disease[J]. J Neurochem, 2007, 103(3): 1237–1257

[16] Constantinou C, Karavia EA, Xepapadaki E, Advances in high density lipoprotein physiology: surprises, overturns and promises[J]. Am J Physiol Endocrinol Metab, 2016, 310(1): E1–E14.

[17] Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders[J]. Neuron, 2008, 57(2): 178–201

[18] Lehtinen MK, Bjornsson CS, Dymecki SM, The choroid plexus and cerebrospinal fluid: emerging roles in development, disease, and therapy[J]. J Neurosci, 2013, 33(45): 17553–17559.

[19] Dietschy JM, Turley SD. Cholesterol metabolism in the brain[J]. Curr Opin Lipidol, 2001, 12(2): 105–112

[20] Björkhem I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain[J]. J Intern Med, 2006, 260(6): 493–508

[21] Linton MF, Gish R, Hubl ST, Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation[J]. J Clin Invest, 1991, 88(1): 270–281

[22] Vitali C, Wellington CL, Calabresi L. HDL and cholesterol handling in the brain[J]. Cardiovasc Res, 2014, 103(3): 405–413

[23] Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer’s disease[J]. Annu Rev Neurosci, 1996, 19: 53–77

[24] Koch S, Donarski N, Goetze K, Characterization of four lipoprotein classes in human cerebrospinal fluid[J]. J Lipid Res, 2001, 42(7): 1143–1151

[25] Maiti TK, Konar S, Bir S, Role of apolipoprotein E polymorphism as a prognostic marker in traumatic brain injury and neurodegenerative disease: a critical review[J]. Neurosurg Focus, 2015, 39(5): E3

[26] Zannis VI, Chroni A, Kypreos KE, Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer[J]. Curr Opin Lipidol, 2004, 15(2): 151–166

[27] Zannis VI, Kypreos KE, Chroni A, Lipoproteins and atherogenesis. In: Loscalzo J, ed. Molecular Mechanisms of Atherosclerosis[M]. New York, NY: Taylor & Francis, 2004: 111–174.

[28] Havel RJ, Kotite L, Vigne JL, Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. Concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency[J]. J Clin Invest, 1980, 66(6): 1351–1362

[29] Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3[J]. Arterioscler Thromb Vasc Biol, 1999, 19(3): 472–484

[30] Huang Y, Liu XQ, Rall SC Jr, Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia[J]. J Biol Chem, 1998, 273(41): 26388–26393

[31] Huang Y, Liu XQ, Rall SC Jr. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins[J]. J Biol Chem, 1998, 273(28):17483–17490.

[32] Rensen PC, van Berkel TJ. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo[J]. J Biol Chem, 1996, 271(25): 14791–14799

[33] Filou S, Lhomme M, Karavia EA, Distinct roles of apolipoproteins A1 and E in the modulation of high-density lipoprotein composition and function[J]. Biochemistry, 2016, 55(27): 3752–3762

[34] Kypreos KE, Zannis VI. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT[J]. Biochem J, 2007, 403(2): 359–367

[35] Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man[J]. Nature, 1977, 269(5629): 604–607

[36] Havel RJ, Kane JP. Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins[J]. Proc Natl Acad Sci U S A, 1973, 70(7): 2015–2019

[37] Eichner JE, Dunn ST, Perveen G, Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review[J]. Am J Epidemiol, 2002, 155(6): 487–495

[38] Wilson PW, Schaefer EJ, Larson MG, Apolipoprotein E alleles and risk of coronary disease. A meta-analysis[J]. Arterioscler Thromb Vasc Biol, 1996, 16(10): 1250–1255

[39] Plump AS, Smith JD, Hayek T, Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells[J]. Cell, 1992, 71(2): 343–353

[40] Chiba T, Nakazawa T, Yui K, VLDL induces adipocyte differentiation in ApoE-dependent manner[J]. Arterioscler Thromb Vasc Biol, 2003, 23(8): 1423–1429

[41] Huang ZH, Reardon CA, Mazzone T. Endogenous ApoE expression modulates adipocyte triglyceride content and turnover[J]. Diabetes, 2006, 55(12): 3394–3402

[42] Hofmann SM, Perez-Tilve D, Greer TM, Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice[J]. Diabetes, 2008, 57(1): 5–12

[43] Gao J, Katagiri H, Ishigaki Y, Involvement of apolipoprotein E in excess fat accumulation and insulin resistance[J]. Diabetes, 2007, 56(1): 24–33

[44] Karagiannides I, Abdou R, Tzortzopoulou A, Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice[J]. FEBS J, 2008, 275(19): 4796–4809.

[45] Zvintzou E, Skroubis G, Chroni A, Effects of bariatric surgery on HDL structure and functionality: results from a prospective trial[J]. J Clin Lipidol, 2014, 8(4): 408–417

[46] Hofmann SM, Perez-Tilve D, Greer TM, Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice[J]. Diabetes, 2008, 57(1): 5– 12

[47] Kypreos KE, Teusink B, Van Dijk KW, Analysis of the structure and function relationship of the human apolipoprotein E in vivo, using adenovirus-mediated gene transfer[J]. FASEB J, 2001, 15(9): 1598–1600

[48] Yamamoto T, Choi HW, Ryan RO. Apolipoprotein E isoform-specific binding to the low-density lipoprotein receptor[J]. Anal Biochem, 2008, 372(2): 222–226

[49] Ruiz J, Kouiavskaia D, Migliorini M, The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor[J]. J Lipid Res, 2005, 46(8): 1721–1731

[50] Li X, Kypreos K, Zanni EE, Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain[J]. Biochemistry, 2003, 42(35): 10406–10417

[51] Ruiz-Carrilo A, Beato M, Schutz G, Cell-free translation of the globin message within polydisperse high-molecular-weight ribonucleic acid of avian erythrocytes[J]. Proc Natl Acad Sci U S A, 1973, 70(12): 3641–3645

[52] Schreyer SA, Vick C, Lystig TC, LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice[J]. Am J Physiol Endocrinol Metab, 2002, 282(1): E207–E214

[53] Karavia EA, Papachristou DJ, Kotsikogianni I, Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice[J]. FEBS J, 2011, 278(17): 3119–3129

[54] Hofmann SM, Zhou L, Perez-Tilve D, Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice[J]. J Clin Invest, 2007, 117(11): 3271–3282

[55] Martens K, Bottelbergs A, Baes M. Ectopic recombination in the central and peripheral nervous system by aP2/FABP4-Cre mice: implications for metabolism research[J]. FEBS Lett, 2010, 584(5): 1054–1058

[56] Jeffery E, Berry R, Church CD, Characterization of Cre recombinase models for the study of adipose tissue[J]. Adipocyte, 2014, 3(3): 206–211.

[57] Hatziri A, Kalogeropoulou C, Xepapadaki E, Site-specific effects of apolipoprotein E expression on diet-induced obesity and white adipose tissue metabolic activation[J]. Biochim Biophys Acta, 2018, 1864(2): 471–480

[58] Liu Q, Zhang J, Zerbinatti C, Lipoprotein receptor LRP1 regulates leptin signaling and energy homeostasis in the adult central nervous system[J]. PLoS Biol, 2011, 9(1): e1000575

[59] Arbones-Mainar JM, Johnson LA, Altenburg MK, Differential modulation of diet-induced obesity and adipocyte functionality by human apolipoprotein E3 and E4 in mice[J]. Int J Obes (Lond), 2008, 32(10): 1595–1605

[60] Zaiss AK, Liu Q, Bowen GP, Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors[J]. J Virol, 2002, 76(9): 4580–4590

[61] Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined[J]. Am J Hum Genet, 1981, 33(1): 11–24

[62] Breslow JL, McPherson J, Nussbaum AL, Identification and DNA sequence of a human apolipoprotein E cDNA clone[J]. J Biol Chem, 1982, 257(24): 14639–14641

[63] Breslow JL, Zannis VI, SanGiacomo TR, Studies of familial type Ⅲ hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2[J]. J Lipid Res, 1982, 23(8): 1224–1235

[64] Zannis VI, Breslow JL, Utermann G, Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes[J]. J Lipid Res, 1982, 23(6): 911–914

[65] Zannis VI, Breslow JL. Apolipoprotein E[J]. Mol Cell Biochem, 1982, 42(1): 3–20

[66] Wagner T, Bartelt A, Schlein C, Genetic dissection of tissue-specific apolipoprotein E function for hypercholesterolemia and diet-induced obesity[J]. PLoS One, 2015, 10(12): e0145102

[67] Kypreos KE, van Dijk KW, van Der Zee A, Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion[J]. J Biol Chem, 2001, 276(23): 19778–19786

[68] Kypreos KE, van Dijk KW, Havekes LM, Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia[J]. J Biol Chem, 2005, 280(8): 6276–6284

[69] Drosatos K, Kypreos KE, Zannis VI. Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoprotein[J]. Biochemistry, 2007, 46(33): 9645–9653

Acknowledgments

Dr. Eleni A. Karavia and Ms. Eva Xepapadaki are supported by a Postdoc-Research Scholarship (2017-2019), and a graduate studentship (2017-2019) respectively, both funded by the State Scholarships Foundation (I.K.Y) of Greece.

RIGHTS & PERMISSIONS

2018 2018 by the Journal of Biomedical Research.